Zulresso Is Sage’s First Step In Postpartum Depression Treatment
Executive Summary
I.V. Zulresso is the first US FDA-approved drug for postpartum depression (PPD) and Sage's first commercial product – with a list price of $34,000. It will help the company build a presence in PPD as it completes late-stage development for oral candidate SAGE-217.
You may also be interested in...
Sage Readies Zurzuvae For December Launch With Slow Ramp As Payer Talks Progress
Sage and Biogen set a $15,900 list price for Zurzuvae, the 14-day postpartum depression drug approved in the US in August, and expect broad access but formulary discussions will continue into 2024.
Sage/Biogen See Big Potential Market For Zuranolone In PPD
The companies reported positive Phase III data in postpartum depression, a market opportunity of up to half a million women in the US with a condition that remains underdiagnosed.
Biogen/Sage’s Zuranolone Data May Not Be Enough For Tough Commercial Landscape
The drug may have enough efficacy for approval, but data fell short of the benchmark seen as necessary for commercial adoption